4Ellis W J, Vessella R L, Buhler K R, et al. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft LuCaP23[J]. Clin Cancer Res, 1996,2(6): 1039- 1048.
5Van Weerden W M, de Ridder C M, Verdaasdonk C L, et al. Development of seven new human prostate tumor xenograft models and their histopathological characterization[J]. Am J Pathol, 1996,149(3):1055-1062.
6Masumori N, Thomas T Z, Chaurand P, et al. A probasin-large T antigen transgenie mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential[J]. Cancer Res, 2001,61 (5):2239-2249.
7Asamoto M, Hokaiwado N,Cho Y M, et al. Effects of genetic background on prostate and taste bud carcinogenesis due to SV40 T antigene expression under probasin gene promoter control [J]. Carcinogenesis, 2002,23(3):463-467.
8Zhang J, Thomas T Z, Kasper S, et al. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and clucocorticoids in vitro and in vivo[J]. Endocrinology, 2000,141(12):4698-4710.
9Voelkel-Johnson C, Voeks D J, Greenberg N M, et al. Genomie instability-based transgenic models of prostate cancer [J]. Carcinogenesis, 2000,21(8):1623-1627.
10Furuhata S, lde H, Miura Y, et al. Development of a prostate-specific promoter for gene therapy against androgen-independent prostate cancer[J]. Mol Ther, 2003,7(3):366-374.
